المؤلفون: Kim, Michelle M, Mehta, Minesh P, Smart, DeeDee K, Steeg, Patricia S, Hong, Julie A, Espey, Michael G, Prasanna, Pataje G, Crandon, Laura, Hodgdon, Christine, Kozak, Niki, Armstrong, Terri S, Morikawa, Aki, Willmarth, Nicole, Tanner, Kirk, Boire, Adrienne, Gephart, Melanie Hayden, Margolin, Kim A, Hattangadi-Gluth, Jona, Tawbi, Hussein, Trifiletti, Daniel M, Chung, Caroline, Basu-Roy, Upal, Burns, Robyn, Oliva, Isabella C Glitza, Aizer, Ayal A, Anders, Carey K, Davis, Joanne, Ahluwalia, Manmeet S, Chiang, Veronica, Li, Jing, Kotecha, Rupesh, Formenti, Silvia C, Ellingson, Benjamin M, Gondi, Vinai, Sperduto, Paul W, Barnholtz-Sloan, Jill S, Rodon, Jordi, Lee, Eudocia Q, Khasraw, Mustafa, Yeboa, Debra Nana, Brastianos, Priscilla K, Galanis, Evanthia, Coleman, C Norman, Ahmed, Mansoor M

المصدر: The Lancet Oncology. 24(8)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Brain Cancer, Rare Diseases, Clinical Research, Cancer, Brain Disorders, Good Health and Well Being, United States, Humans, Quality of Life, National Cancer Institute (U.S.), Biomedical Research, Consensus, Brain Neoplasms, Oncology & Carcinogenesis, Oncology and carcinogenesis

الوصف: Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient survival, function, and quality of life, mandating a multidimensional approach to clinical care and research. At a virtual National Cancer Institute Workshop in September, 2022, key stakeholders convened to define research priorities to address the crucial areas of unmet need for patients with brain metastases to achieve meaningful advances in patient outcomes. This Policy Review outlines existing knowledge gaps, collaborative opportunities, and specific recommendations regarding consensus priorities and future directions in brain metastases research. Achieving major advances in research will require enhanced coordination between the ongoing efforts of individual organisations and consortia. Importantly, the continual and active engagement of patients and patient advocates will be necessary to ensure that the directionality of all efforts reflects what is most meaningful in the context of patient care.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5tt7g1r4Test

المؤلفون: Oppegaard, Kate R, Mayo, Samantha J, Armstrong, Terri S, Kober, Kord M, Anguera, Joaquin A, Wright, Fay, Levine, Jon D, Conley, Yvette P, Paul, Steven, Cooper, Bruce, Miaskowski, Christine

المصدر: Nursing Research. 72(4)

مصطلحات موضوعية: Health Services and Systems, Nursing, Health Sciences, Brain Disorders, Behavioral and Social Science, Acquired Cognitive Impairment, Cancer, Clinical Research, 7.1 Individual care needs, Management of diseases and conditions, Adult, Humans, Longitudinal Studies, Cognitive Dysfunction, Cognition, Outpatients, Neoplasms, cancer, chemotherapy, cognitive impairment, conceptual model, depression, fatigue, patient-reported outcomes, sleep disturbance, social determinants of health, structural equation model, Midwifery

الوصف: BackgroundUp to 45% of patients report cancer-related cognitive impairment (CRCI). A variety of characteristics are associated with the occurrence and/or severity of CRCI. However, an important gap in knowledge of risk factors for CRCI is the relative contribution of each factor. The multifactorial model of cancer-related cognitive impairment (MMCRCI) is a conceptual model of CRCI that can be used to evaluate the strength of relationships between various factors and CRCI.ObjectivesThe purpose of this study was to use structural regression methods to evaluate the MMCRCI using data from a large sample of outpatients receiving chemotherapy ( n = 1,343). Specifically, the relationships between self-reported CRCI and four MMCRCI concepts (i.e., social determinants of health, patient-specific factors, treatment factors, and co-occurring symptoms) were examined. The goals were to determine how well the four concepts predicted CRCI and determine the relative contribution of each concept to deficits in perceived cognitive function.MethodsThis study is part of a larger, longitudinal study that evaluated the symptom experience of oncology outpatients receiving chemotherapy. Adult patients were diagnosed with breast, gastrointestinal, gynecological, or lung cancer; had received chemotherapy within the preceding 4 weeks; were scheduled to receive at least two additional cycles of chemotherapy; were able to read, write, and understand English; and gave written informed consent. Self-reported CRCI was assessed using the attentional function index. Available study data were used to define the latent variables.ResultsOn average, patients were 57 years of age, college educated, and with a mean Karnofsky Performance Status score of 80. Of the four concepts evaluated, whereas co-occurring symptoms explained the largest amount of variance in CRCI, treatment factors explained the smallest amount of variance. A simultaneous structural regression model that estimated the joint effect of the four exogenous latent variables on the CRCI latent variable was not significant.DiscussionThese findings suggest that testing individual components of the MMCRCI may provide useful information on the relationships among various risk factors, as well as refinements of the model. In terms of risk factors for CRCI, co-occurring symptoms may be more significant than treatment factors, patient-specific factors, and/or social determinants of health in patients receiving chemotherapy.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/85q7k310Test

المؤلفون: Millward, Christopher P, Armstrong, Terri S, Barrington, Heather, Brodbelt, Andrew R, Bulbeck, Helen, Byrne, Anthony, Dirven, Linda, Gamble, Carrol, Grundy, Paul L, Islim, Abdurrahman I, Javadpour, Mohsen, Keshwara, Sumirat M, Krishna, Sandhya T, Mallucci, Conor L, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Pizer, Barry, Plaha, Puneet, Preusser, Matthias, Santarius, Thomas, Srikandarajah, Nisaharan, Taphoorn, Martin JB, Watts, Colin, Weller, Michael, Williamson, Paula R, Zadeh, Gelareh, Najafabadi, Amir H Zamanipoor, Jenkinson, Michael D

المصدر: Neuro-Oncology. 24(7)

مصطلحات موضوعية: Clinical Trials and Supportive Activities, Rare Diseases, Neurosciences, Clinical Research, Cancer, Brain Disorders, Brain Cancer, Evaluation of treatments and therapeutic interventions, 6.9 Resources and infrastructure (treatment evaluation), Generic health relevance, Adult, Child, Consensus, Delphi Technique, Humans, Meningeal Neoplasms, Meningioma, Research Design, Treatment Outcome, clinical trial, core outcome set, effectiveness, glioma, meningioma, Oncology and Carcinogenesis, Oncology & Carcinogenesis

الوصف: Core Outcome Sets (COS) define minimum outcomes to be measured and reported in clinical effectiveness trials for a particular health condition/health area. Despite recognition as critical to clinical research design for other health areas, none have been developed for neuro-oncology. COS development projects should carefully consider: scope (how the COS should be used), stakeholders involved in development (including patients as both research partners and participants), and consensus methodologies used (typically a Delphi survey and consensus meeting), as well as dissemination plans. Developing COS for neuro-oncology is potentially challenging due to extensive tumor subclassification (including molecular stratification), different symptoms related to anatomical tumor location, and variation in treatment options. Development of a COS specific to tumor subtype, in a specific location, for a particular intervention may be too narrow and would be unlikely to be used. Equally, a COS that is applicable across a wider area of neuro-oncology may be too broad and therefore lack specificity. This review describes why and how a COS may be developed, and discusses challenges for their development, specific to neuro-oncology. The COS under development are briefly described, including: adult glioma, incidental/untreated meningioma, meningioma requiring intervention, and adverse events from surgical intervention for pediatric brain tumors.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/1hn2z6n0Test

المؤلفون: Millward, Christopher P, Armstrong, Terri S, Barrington, Heather, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Crofton, Anna, Dirven, Linda, Georgious, Theo, Grundy, Paul L, Islim, Abdurrahman I, Javadpour, Mohsen, Keshwara, Sumirat M, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias, Santarius, Thomas, Srikandarajah, Nisaharan, Taphoorn, Martin JB, Turner, Carole, Watts, Colin, Weller, Michael, Williamson, Paula R, Zadeh, Gelareh, Najafabadi, Amir H Zamanipoor, Jenkinson, Michael D, Aldape, Kenneth, Au, Karolyn, Barnhartz-Sloan, Jill, Bi, Wenya Linda, Behling, Felix, Brastianos, Priscilla K, Brodie, Chaya, Butowski, Nicholas, Carlotti, Carlos, Castro, Ana, Cohen-Gadol, Aaron, Couce, Marta, Cusimano, Michael D, DiMeco, Francesco, Drummond, Katharine, Dunn, Ian F, Erker, Craig, Felicella, Michelle, Fountain, Daniel M, Galanis, Evanthia, Galldiks, Norbert, Giannini, Caterina, Goldbrunner, Roland, Griffith, Brent, Hashizume, Rintaro, Hanemann, C Oliver, Herold-Mende, Christel, Hnenny, Luke, Horbinski, Craig, Huang, Raymond Y, James, David, Jungk, Christine, Jungwirth, Gerhard, Kaufmann, Timothy J, Krischek, Boris, Kurz, Sylvia, Lachance, Daniel, Lafougère, Christian, Lamszus, Katrin, Lee, Ian, Liu, Jeff C, Makarenko, Serge, Malta, Tathiana, Mamatjan, Yasin, Mansouri, Alireza, Mawrin, Christian, McDermott, Michael, Moliterno-Gunel, Jennifer, Morokoff, Andrew, Munoz, David, Nassiri, Farshad, Noushmehr, Houtan, Ng, Ho-Keung, Perry, Arie, Pirouzmand, Farhad, Poisson, Laila M, Pollo, Bianca, Ragunathan, Aditya, Raleigh, David, Renovanz, Mirjam, Ricklefs, Franz, Sahm, Felix, Saladino, Andrea, Santacroce, Antonio, Schittenhelm, Jens, Schichor, Christian

المصدر: BMJ Open. 12(5)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Neurosciences, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Consensus, Delphi Technique, Humans, Meningeal Neoplasms, Meningioma, Research Design, Systematic Reviews as Topic, Treatment Outcome, EORTC BTG, ICOM, EANO, SNO, RANO-PRO, BNOS, SBNS, BIMS, TBTC, International Brain Tumour Alliance, Brainstrust, and Brain Tumour Foundation of Canada, clinical trial, core outcome set, meningioma, Public Health and Health Services, Other Medical and Health Sciences, Biomedical and clinical sciences, Health sciences, Psychology

الوصف: IntroductionMeningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two 'Core Outcome Sets' (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma.Methods and analysisTwo systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups.Ethics and disseminationInstitutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available.Trial registration numberCOMET study ID 1508.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/6n20x5mdTest

المؤلفون: Pratt, Drew, Abdullaev, Zied, Papanicolau-Sengos, Antonios, Ketchum, Courtney, Panneer Selvam, Pavalan, Chung, Hye-Jung, Lee, Ina, Raffeld, Mark, Gilbert, Mark R, Armstrong, Terri S, Pytel, Peter, Borys, Ewa, Klonoski, Joshua M, McCord, Matthew, Horbinski, Craig, Brat, Daniel, Perry, Arie, Solomon, David, Eberhart, Charles, Giannini, Caterina, Quezado, Martha, Aldape, Kenneth

المصدر: Acta Neuropathologica. 143(3)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Cancer, Cancer, Human Genome, Genetics, Neurosciences, Rare Diseases, Brain Disorders, Astrocytoma, Brain Neoplasms, Chromosomes, Human, Pair 13, Glioma, Humans, Middle Aged, Monosomy, Mutation, Tumor Suppressor Protein p53, Neurology & Neurosurgery

الوصف: Tumors of the central nervous system (CNS) often display a wide morphologic spectrum that has, until recently, been the sole basis for tumor classification. The introduction of the integrated histomolecular diagnostic approach in CNS tumors has facilitated a classification system that is increasingly data-driven and with improved alignment to clinical outcome. Here, we report a previously uncharacterized glioma type (n = 31) using unsupervised clustering analysis of DNA methylation array data from approximately 14,000 CNS tumor samples. Histologic examination revealed circumscribed growth and morphologic similarities to pleomorphic xanthoastrocytoma (PXA), astroblastoma, ependymoma, polymorphous neuroepithelial tumor of the young (PLNTY), and IDH-wildtype glioblastoma (GBM). Median age (46.5 years) was significantly older than other circumscribed gliomas and younger than GBM. Dimensionality reduction with uniform manifold approximation and projection (UMAP) and hierarchical clustering confirmed a methylation signature distinct from known tumor types and methylation classes. DNA sequencing revealed recurrent mutations in TP53 (57%), RB1 (26%), NF1 (26%), and NF2 (14%). BRAF V600E mutations were detected in 3/27 sequenced cases (12%). Copy number analysis showed increased whole chromosome aneuploidy with recurrent loss of chromosome 13 (28/31 cases, 90%). CDKN2A/B deletion (2/31, 6%) and MGMT promoter methylation (1/31, 3%) were notably rare events. Most tumors showed features of a high-grade glioma, yet survival data showed significantly better overall survival compared to GBM (p

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/6pg1h4fqTest

المؤلفون: Aboud, Orwa, Shah, Ritu, Vera, Elizabeth, Burton, Eric, Theeler, Brett, Wu, Jing, Boris, Lisa, Quezado, Martha, Reyes, Jennifer, Wall, Kathleen, Gilbert, Mark R, Armstrong, Terri S, Penas-Prado, Marta

المصدر: CNS Oncology. 11(01)

مصطلحات موضوعية: Clinical Research, Rare Diseases, Biomedical Imaging, Brain Neoplasms, Diffusion Magnetic Resonance Imaging, Humans, Neoplasm Grading, Oligodendroglioma, Reproducibility of Results, Retrospective Studies, calcification, contrast enhancement, examiner concordance, interrater reliability, necrosis, oligodendroglioma, restricted diffusion

الوصف: Background: To illustrate challenges of imaging interpretation in patients with oligodendroglioma seen at a referral center and evaluate interrater reliability. Methods: Two neuro-oncologists reviewed diagnostic preradiation MRIs of oligodendroglioma patients; interrater reliability was calculated with the kappa coefficient (k). A neuroradiologist measured presurgical apparent diffusion coefficient (ADC), if available. Results: Extensive enhancement was noted in four of 58 patients, k = 0.7; necrosis in seven of 58, k = 0.61; calcification in seven of 17, k = 1.0; diffusion restriction in two of 39 patients, k = 1.0 (all only in grade 3). ADC values with receiver operator characteristic analysis for area under the curve were 0.473, not significantly different from the null hypothesis (p = 0.14). Conclusions: Extensive enhancement, necrosis and calcification correlated with grade 3 oligodendroglioma in our sample. However, interrater variability is an important limitation when assessing radiographic features, supporting the need for standardization of imaging protocols and their interpretation.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5727n86bTest

المؤلفون: Millward, Christopher P, Keshwara, Sumirat M, Armstrong, Terri S, Barrington, Heather, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Dirven, Linda, Grundy, Paul L, Islim, Abdurrahman I, Javadpour, Mohsen, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias, Santarius, Thomas, Srikandarajah, Nisaharan, Taphoorn, Martin J B, Turner, Carole, Watts, Colin, Weller, Michael, Williamson, Paula R, Zadeh, Gelareh, Zamanipoor Najafabadi, Amir H, Jenkinson, Michael D, Aldape, Kenneth

المصدر: Millward, Christopher P; Keshwara, Sumirat M; Armstrong, Terri S; Barrington, Heather; Bell, Sabrina; Brodbelt, Andrew R; Bulbeck, Helen; Dirven, Linda; Grundy, Paul L; Islim, Abdurrahman I; Javadpour, Mohsen; Koszdin, Shelli D; Marson, Anthony G; McDermott, Michael W; Meling, Torstein R; Oliver, Kathy; Plaha, Puneet; Preusser, Matthias; Santarius, Thomas; Srikandarajah, Nisaharan; Taphoorn, Martin J B; Turner, Carole; Watts, Colin; Weller, Michael; Williamson, Paula R; Zadeh, Gelareh; Zamanipoor Najafabadi, Amir H; Jenkinson, Michael D; Aldape, Kenneth; et al (2024). The outcomes measured and reported in intracranial meningioma clinical trials: A systematic review. Neuro-oncology advances, 6(1):vdae030.

مصطلحات موضوعية: Clinic for Neurology, 610 Medicine & health

الوصف: Background Meningioma clinical trials have assessed interventions including surgery, radiotherapy, and pharmacotherapy. However, agreement does not exist on what, how, and when outcomes of interest should be measured. To do so would allow comparative analysis of similar trials. This systematic review aimed to summarize the outcomes measured and reported in meningioma clinical trials. Methods Systematic literature and trial registry searches were performed to identify published and ongoing intracranial meningioma clinical trials (PubMed, Embase, Medline, CINAHL via EBSCO, and Web of Science, completed January 22, 2022). Reported outcomes were extracted verbatim, along with an associated definition and method of measurement if provided. Verbatim outcomes were deduplicated and the resulting unique outcomes were grouped under standardized outcome terms. These were classified using the taxonomy proposed by the “Core Outcome Measures in Effectiveness Trials” (COMET) initiative. Results Thirty published articles and 18 ongoing studies were included, describing 47 unique clinical trials: Phase 2 n = 33, phase 3 n = 14. Common interventions included: Surgery n = 13, radiotherapy n = 8, and pharmacotherapy n = 20. In total, 659 verbatim outcomes were reported, of which 84 were defined. Following de-duplication, 415 unique verbatim outcomes remained and were grouped into 115 standardized outcome terms. These were classified using the COMET taxonomy into 29 outcome domains and 5 core areas. Conclusions Outcome measurement across meningioma clinical trials is heterogeneous. The standardized outcome terms identified will be prioritized through an eDelphi survey and consensus meeting of key stakeholders (including patients), in order to develop a core outcome set for use in future meningioma clinical trials.

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/260265/1/ZORA_download.pdfTest; info:pmid/38596717; urn:issn:2632-2498

الإتاحة: https://doi.org/10.5167/uzh-26026510.1093/noajnl/vdae030Test
https://www.zora.uzh.ch/id/eprint/260265Test/
https://www.zora.uzh.ch/id/eprint/260265/1/ZORA_download.pdfTest

المؤلفون: Millward, Christopher P, Islim, Abdurrahman I, Armstrong, Terri S, Barrington, Heather, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Dirven, Linda, Grundy, Paul L, Javadpour, Mohsen, Keshwara, Sumirat M, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias, Santarius, Thomas, Srikandarajah, Nisaharan, Taphoorn, Martin J B, Turner, Carole, Watts, Colin, Weller, Michael, Williamson, Paula R, Zadeh, Gelareh, Zamanipoor Najafabadi, Amir H, Jenkinson, Michael D, Aldape, Kenneth

المصدر: Millward, Christopher P; Islim, Abdurrahman I; Armstrong, Terri S; Barrington, Heather; Bell, Sabrina; Brodbelt, Andrew R; Bulbeck, Helen; Dirven, Linda; Grundy, Paul L; Javadpour, Mohsen; Keshwara, Sumirat M; Koszdin, Shelli D; Marson, Anthony G; McDermott, Michael W; Meling, Torstein R; Oliver, Kathy; Plaha, Puneet; Preusser, Matthias; Santarius, Thomas; Srikandarajah, Nisaharan; Taphoorn, Martin J B; Turner, Carole; Watts, Colin; Weller, Michael; Williamson, Paula R; Zadeh, Gelareh; Zamanipoor Najafabadi, Amir H; Jenkinson, Michael D; Aldape, Kenneth; et al (2024). The outcomes measured and reported in observational studies of incidental and untreated intracranial meningioma: A systematic review. Neuro-oncology advances, 6(1):vdae042.

مصطلحات موضوعية: Clinic for Neurology, 610 Medicine & health

الوصف: Background The clinical management of patients with incidental intracranial meningioma varies markedly and is often based on clinician choice and observational data. Heterogeneous outcome measurement has likely hampered knowledge progress by preventing comparative analysis of similar cohorts of patients. This systematic review aimed to summarize the outcomes measured and reported in observational studies. Methods A systematic literature search was performed to identify published full texts describing active monitoring of adult cohorts with incidental and untreated intracranial meningioma (PubMed, EMBASE, MEDLINE, and CINAHL via EBSCO, completed January 24, 2022). Reported outcomes were extracted verbatim, along with an associated definition and method of measurement if provided. Verbatim outcomes were de-duplicated and the resulting unique outcomes were grouped under standardized outcome terms. These were classified using the taxonomy proposed by the “Core Outcome Measures in Effectiveness Trials” (COMET) initiative. Results Thirty-three published articles and 1 ongoing study were included describing 32 unique studies: study designs were retrospective n = 27 and prospective n = 5. In total, 268 verbatim outcomes were reported, of which 77 were defined. Following de-duplication, 178 unique verbatim outcomes remained and were grouped into 53 standardized outcome terms. These were classified using the COMET taxonomy into 9 outcome domains and 3 core areas. Conclusions Outcome measurement across observational studies of incidental and untreated intracranial meningioma is heterogeneous. The standardized outcome terms identified will be prioritized through an eDelphi survey and consensus meeting of key stakeholders (including patients), in order to develop a Core Outcome Set for use in future observational studies.

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/260264/1/ZORA_vdae042.pdfTest; info:pmid/38596715; urn:issn:2632-2498

الإتاحة: https://doi.org/10.5167/uzh-26026410.1093/noajnl/vdae042Test
https://www.zora.uzh.ch/id/eprint/260264Test/
https://www.zora.uzh.ch/id/eprint/260264/1/ZORA_vdae042.pdfTest

المؤلفون: Leeper, Heather E, Tonorezos, Emily, Mayer, Deborah, Bakitas, Marie, Chang, Susan, Cooley, Mary E, Hervey-Jumper, Shawn, Miaskowski, Christine, Sherwood, Paula, Tsien, Christina, Wallgren, Kimberly, Willmarth, Nicole, Arons, David, Acquaye, Alvina, King, Amanda L, Penas-Prado, Marta, Vera, Elizabeth, Gilbert, Mark R, Armstrong, Terri S, Arzbaecher, Jean, Dionne-Odom, J Nicholas, Fink, Karen, Hayes, Christi, Leeper, Heather, Lollo, Nicole, Loughan, Ashlee, Oliver, Kathy, Roche, Kayla, Stearn, Sylvia, Timmer, Michael, Amidei, Christina, Blakeley, Jaishri, Cachia, David, Cooke, Laura, Cooley, Mary, Gondi, Vinai, Leach, Danielle, Mendoza, Tito, Morgan, Kendall, Nabors, Burt, Naines, Kristie, Rogers, James, Sharma, Akanksha, Wall, Kathleen, Weathers, Shiao-Pei, Wollet, Alex, Boccia, Maria, Camphausen, Kevin, Christ, Alexa, Figuracion, Karl Cristie, Gilbert, Mark, Komlodi-Pasztor, Edina, Lieberman, Frank, Malkin, Mark, Miller, Hope, Paleologos, Nina, Panzer, Marissa, Stout, Nicole, Wen, Patrick, Beam, Sarah, Boris, Lisa, Fonkem, Ekokobe, Jammula, Varna, Kauss, McKenzie, Kim, Yeonju, Ozer, Byram H, Pan, Edward, Pugh, Stephanie, Strowd, Roy, Wu, Jing, Zaghloul, Kareem, Bell, Susan, Dunbar, Erin M, Haynes, Chas, Haynes, Tuesday, Lesser, Glenn, Maher, Molly, Polskin, Lily, Pillai, Tina

المصدر: Neuro-Oncology Advances. 4(1)

مصطلحات موضوعية: Cancer, Clinical Research, Neurosciences, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, NCI-CONNECT, patient-centered care, primary central nervous system cancer, survivorship, survivorship care, NCI-CONNECT Survivorship Care in Neuro-Oncology Workshop

الوصف: BackgroundSurvivorship for those living with primary CNS cancers begins at diagnosis, continues throughout a person's life, and includes caregivers. Opportunities and challenges exist to advance survivorship care for those living with primary CNS cancers that necessitate stakeholder involvement.MethodsIn June 2021, NCI-CONNECT convened a two-day virtual workshop about survivorship care in neuro-oncology. Two expert panels provided key recommendations and five working groups considered critical questions to identify strengths, weaknesses, opportunities, and threats to the advancement of survivorship care and developed recommendations and action items.ResultsThe following action items emanated from the workshop: seek endorsement of meeting report from stakeholder organizations; address barriers in access to survivorship care and provider reimbursement; advance survivorship research through NIH and private grant support; develop a survivorship tool kit for providers, people living with primary CNS cancers and their caregivers; provide accessible educational content for neuro-oncology, neurology, and oncology community providers about survivorship care in neuro-oncology; and establish core competencies for survivorship care for neuro-oncology providers to be included in training and standardized exams.ConclusionsAction items aim to address access and reimbursement barriers, expand patient and provider education, develop core competencies, and support survivorship research through funding and other supports.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/61r2s3pwTest

المؤلفون: Sass, Dilorom, Fitzgerald, Wendy, Wolff, Brian S, Torres, Isaias, Pagan-Mercado, Glorivee, Armstrong, Terri S, Miaskowski, Christine, Margolis, Leonid, Saligan, Leorey, Kober, Kord M

مصطلحات موضوعية: breast cancer, cytokines, extracellular vesicles, latent class, symptoms, Pain Research, Cancer, Clinical Research, Aging, Breast Cancer, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Genetics, Clinical Sciences, Law

الوصف: Because extracellular vesicle (EV)-associated cytokines, both encapsulated and surface bound, have been associated with symptom severity, and may vary over the lifespan, they may be potential biomarkers to uncover underlying mechanisms of various conditions. This study evaluated the associations of soluble and EV-associated cytokine concentrations with distinct symptom profiles reported by 290 women with breast cancer prior to surgery. Patients were classified into older (≥60 years, n = 93) and younger (< 60 years, n = 197) cohorts within two previously identified distinct symptom severity profiles, that included pain, depressive symptoms, sleep disturbance, and fatigue (i.e., High Fatigue Low Pain and All Low). EVs were extracted using ExoQuick. Cytokine concentrations were determined using Luminex multiplex assay. Mann Whitney U test evaluated the differences in EV and soluble cytokine levels between symptom classes and between and within the older and younger cohorts adjusting for Karnofsky Performance Status (KPS) score, body mass index (BMI), and stage of disease. Partial correlation analyses were run between symptom severity scores and cytokine concentrations. Results of this study suggest that levels of cytokine concentrations differ between EV and soluble fractions. Several EV and soluble pro-inflammatory cytokines had positive associations with depressive symptoms and fatigue within both age cohorts and symptom profiles. In addition, in the older cohort with High Fatigue Low Pain symptom profile, EV GM-CSF concentrations were higher compared to the All Low symptom profile (p < 0.05). Albeit limited by a small sample size, these exploratory analyses provide new information on the association between cytokines and symptom profiles of older and younger cohorts. Of note, unique EV-associated cytokines were found in older patients and in specific symptom classes. These results suggest that EVs may be potential biomarker discovery tools. Understanding the mechanisms that underlie distinct symptom class profiles categorized by age may inform intervention trials and offer precision medicine approaches.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/6456b1n7Test